Correct laboratory approach to APS diagnosis and monitoring

Autoimmunity Reviews

Volumn 12, Issue 8, 2013, Pages 832-834

  Pengo, V ^a   Banzato, A ^a   Denas, G ^a   Jose, S Padayattil ^a   Bison, E ^a   Hoxha, A ^a   Ruffatti, A ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Antiphospholipid Syndrome; Lupus anticoagulant; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR H; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTICARDIOLIPIN ANTIBODY ENZYME LINKED IMMUNOSORBENT ASSAY; ANTIPHOSPHOLIPID SYNDROME; BETA2 GLYCOPROTEIN 1 ANTIBODY ENZYME LINKED IMMUNOSORBENT ASSAY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; PATHOGENESIS; REVIEW; RISK FACTOR; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 84878619290     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.11.008     Document Type: Review

References (36)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827-1832.
3. Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005, 93:1147-1152.
4. Pengo V., Biasiolo A., Gresele P., Marongiu F., Erba N., Veschi F., et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol 2007, 27:e309-e310.
5. de Groot P.G., Lutters B., Derksen R.H., Lisman T., Meijers J.C., Rosendaal F.R. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005, 3:1993-1997.
6. de Laat H.B., Derksen R.H.W.M., Urbanus R.T., Roest M., de Groot P.G. β2-glycoprotein I dependent lupus anticoagulant highly correlates with thrombosis in the Antiphospholipid Syndrome. Blood 2004, 104:3598-3602.
7. de Laat B., Derksen R.H., Urbanus R.T., de Groot P.G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood 2005, 105:1540-1545.
8. Simmelink M.J., Derksen R.H., Arnout J., de Groot P.G. A simple method to discriminate between beta 2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003, 1:740-747.
9. Pengo V., Biasiolo A., Pegoraro C., Iliceto S. A two-step coagulation test to identify anti-h2-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004, 2:702-707.
10. Rampazzo P., Biasiolo A., Garin J., Rosato A., Betterle C., Ruffatti A., et al. Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb Haemost 2001, 85:57-62.
11. Pengo V., Biasiolo A., Bison E., Chantarangkul V., Tripodi A., Italian Federation of Anticoagulation Clinics (FCSA) Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb Res 2007, 120:127-133.
12. Harris E.N., Gharavi A.E., Hughes G.R. Anticardiolipin antibody testing: the need for standardization. Arthritis Rheum 1987, 30:835-837.
13. Ruffatti A., Olivieri S., Tonello M., Bortolati M., Bison E., Salvan E., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008, 6:1693-1696.
14. Mackworth-Young C.G. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004, 136:393-401.
15. Di Simone N., Meroni P.L., D'Asta M., Di Nicuolo F., D'Ippolito S., D'alessio M.C., et al. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies. A review of the literature. Ann N Y Acad Sci 2007, 1108:505-514.
16. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003, 112:1644-1654.
17. Shamonki J.M., Salmon J.E., Hyjek E., Baergen R.N. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007, 196:167.
18. Galli M., Borrelli G., Jacobsen E.M., Marfisi R.M., Finazzi G., Marchioli R., et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007, 110:1178-1183.
19. Naess I.A., Christiansen S.C., Cannegieter S.C., Rosendaal F.R., Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006, 4:44-49.
20. Runchey S.S., Folsom A.R., Tsai M.Y., Cushman M., McGovern P.D. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002, 119:1005-1010.
21. Urbanus R.T., Siegerink B., Roest M., Rosendaal F.R., de Groot P.G., Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009, 8:998-1005.
22. de Laat B., Pengo V., Pabinger I., Musial J., Voskuyl A.E., Bultink I.E., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009, 7:1767-1773.
23. Garcia C.O., Kanbour-Shakir A., Tang H., Molina J.F., Espinoza L.R., Gharavi A.E. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. Am J Reprod Immunol 1997, 37:118-124.
24. Ruffatti A., Tonello M., Del Ross T., Cavazzana A., Grava C., Noventa F., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006, 96:337-341.
25. Pengo V., Balestrieri G., Tincani A., Spatola L., Biasiolo A., Brocco T. Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. Thromb Haemost 1997, 77:123-126.
26. Banzato A., Pozzi N., Frasson R., De Filippis V., Ruffatti A., Bison E., et al. Antibodies to domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res 2011, 128:583-586.
27. Lee E.Y., Chang-Keun L., Lee T.H., Chung S.M., Kim S.H., Cho Y.S., et al. Does the anti-β2-glycoprotein I antibody provide additional information in patients with thrombosis?. Thromb Res 2003, 111:29-32.
28. Male C., Foulon D., Hogendoorn H., Vee P., Silverman E., David M., et al. Predictive values of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005, 106:4152-4158.
29. Forastiero R., Martinuzzo M., Pombo G., Puente D., Rossi A., Celebrin L., et al. A prospective study of antibodies to β2-GPI and prothrombin and risk of thrombosis. J Thromb Haemost 2005, 3:1231-1238.
30. Galli M. The antphospholipid triangle. J Thromb Haemost 2010, 8:234-236.
31. Pengo V., Bison E., Ruffatti A., Iliceto S. Antibodies to oxidized LDL/beta2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thromb Res 2008, 122:556-559.
32. Pengo V., Ruffatti A., Legnani C., Testa S., Fierro T., Marongiu F., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011, 118:4714-4718.
33. Ames P.R.J., Ciampa A., Margaglione M., Scenna G., Iannaccone L., Brancaccio V. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation. Thromb Haemost 2005, 93:694-699.
34. Roggenbuck D., Egerer K., von Landenberg P., Hiemann R., Feist E., Burmester G.R., et al. Antiphospholipid antibody profiling: time for a new technical approach?. Autoimmun Rev Sep 2012, 11(11):821-826. [Epub 2012 Feb 28]. 10.1016/j.autrev.2012.02.016.
35. Staub H.L., Bertolaccini M.L., Khamashta M.A. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev 2012, 12:230-234.
36. Pengo V., Ruiz-Irastorza G., Denas G., Andreoli L., Khamashta M.A., Tincani A. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome. "PROS" and "CONS". Autoimmun Rev 2012, 11:577-580.